Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ADI DIAB and JONATHAN L CURRY.
Connection Strength

1.919
  1. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
    View in: PubMed
    Score: 0.209
  2. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunol Res. 2019 06; 7(6):860-865.
    View in: PubMed
    Score: 0.169
  3. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019 Sep; 46(9):627-636.
    View in: PubMed
    Score: 0.169
  4. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct; 45(10):786-790.
    View in: PubMed
    Score: 0.161
  5. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol. 2018 Oct; 45(10):764-773.
    View in: PubMed
    Score: 0.161
  6. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018 02 12; 6(1):14.
    View in: PubMed
    Score: 0.156
  7. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. Int J Dermatol. 2019 Sep; 58(9):1045-1052.
    View in: PubMed
    Score: 0.154
  8. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. 2017 Dec; 44(12):1080-1086.
    View in: PubMed
    Score: 0.152
  9. Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 2017; 5:7.
    View in: PubMed
    Score: 0.145
  10. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
    View in: PubMed
    Score: 0.144
  11. A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. J Immunother Cancer. 2016; 4:55.
    View in: PubMed
    Score: 0.142
  12. TERT amplification but not activation of canonical Wnt/?-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Mod Pathol. 2020 10; 33(10):2067-2074.
    View in: PubMed
    Score: 0.046
  13. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers (Basel). 2019 Dec 16; 11(12).
    View in: PubMed
    Score: 0.044
  14. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. Am J Dermatopathol. 2017 Feb; 39(2):121-129.
    View in: PubMed
    Score: 0.036
  15. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.